S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   192.03 (-0.79%)
AAPL   236.13 (+0.36%)
FB   185.92 (-2.35%)
MSFT   138.05 (-1.17%)
AMZN   1,763.32 (-1.35%)
CGC   20.00 (-3.66%)
NVDA   190.73 (-1.83%)
MU   43.47 (-4.46%)
T   38.23 (+1.08%)
F   9.29 (+1.98%)
ACB   3.71 (-4.63%)
NFLX   275.30 (-6.15%)
BAC   30.45 (+0.63%)
GILD   64.23 (-1.53%)
S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   192.03 (-0.79%)
AAPL   236.13 (+0.36%)
FB   185.92 (-2.35%)
MSFT   138.05 (-1.17%)
AMZN   1,763.32 (-1.35%)
CGC   20.00 (-3.66%)
NVDA   190.73 (-1.83%)
MU   43.47 (-4.46%)
T   38.23 (+1.08%)
F   9.29 (+1.98%)
ACB   3.71 (-4.63%)
NFLX   275.30 (-6.15%)
BAC   30.45 (+0.63%)
GILD   64.23 (-1.53%)
Log in

ContraFect Stock Price, News & Analysis (NASDAQ:CFRX)

$0.32
+0.01 (+3.23 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$0.32
Now: $0.32
$0.33
50-Day Range
$0.29
MA: $0.37
$0.42
52-Week Range
$0.27
Now: $0.32
$2.63
Volume17,782 shs
Average Volume235,286 shs
Market Capitalization$25.41 million
P/E RatioN/A
Dividend YieldN/A
Beta0.15
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CFRX
CUSIPN/A
Phone914-207-2300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.07 per share

Profitability

Net Income$-37,680,000.00

Miscellaneous

Employees20
Market Cap$25.41 million
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable

Receive CFRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CFRX and its competitors with MarketBeat's FREE daily newsletter.


ContraFect (NASDAQ:CFRX) Frequently Asked Questions

What is ContraFect's stock symbol?

ContraFect trades on the NASDAQ under the ticker symbol "CFRX."

How were ContraFect's earnings last quarter?

ContraFect Corp (NASDAQ:CFRX) posted its earnings results on Friday, August, 9th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.09). View ContraFect's Earnings History.

When is ContraFect's next earnings date?

ContraFect is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for ContraFect.

What price target have analysts set for CFRX?

2 brokerages have issued twelve-month price objectives for ContraFect's shares. Their forecasts range from $1.50 to $2.00. On average, they anticipate ContraFect's share price to reach $1.75 in the next year. This suggests a possible upside of 446.9% from the stock's current price. View Analyst Price Targets for ContraFect.

What is the consensus analysts' recommendation for ContraFect?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ContraFect.

Has ContraFect been receiving favorable news coverage?

News stories about CFRX stock have been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ContraFect earned a news sentiment score of -2.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for ContraFect.

Are investors shorting ContraFect?

ContraFect saw a drop in short interest in the month of September. As of September 30th, there was short interest totalling 146,800 shares, a drop of 60.7% from the August 30th total of 374,000 shares. Based on an average daily trading volume, of 245,100 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.3% of the company's shares are sold short. View ContraFect's Current Options Chain.

Who are some of ContraFect's key competitors?

What other stocks do shareholders of ContraFect own?

Who are ContraFect's key executives?

ContraFect's management team includes the folowing people:
  • Dr. Steven C. Gilman, Exec. Chairman, CEO & Pres (Age 66)
  • Mr. Michael Messinger CPA, CPA, CFO & Chief Accounting Officer (Age 44)
  • Ms. Nancy Dong, VP of Fin. & Admin. (Age 54)
  • Ms. Natalie Bogdanos J.D., Gen. Counsel, Corp. Sec. & Data Protection Officer (Age 50)
  • Dr. Cara Cassino, Chief Medical Officer and Exec. VP of R&D (Age 57)

Who are ContraFect's major shareholders?

ContraFect's stock is owned by a number of of institutional and retail investors. Top institutional investors include Hartwell J M Limited Partnership (0.25%). View Institutional Ownership Trends for ContraFect.

Which major investors are buying ContraFect stock?

CFRX stock was bought by a variety of institutional investors in the last quarter, including Hartwell J M Limited Partnership. View Insider Buying and Selling for ContraFect.

How do I buy shares of ContraFect?

Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ContraFect's stock price today?

One share of CFRX stock can currently be purchased for approximately $0.32.

How big of a company is ContraFect?

ContraFect has a market capitalization of $25.41 million. The biotechnology company earns $-37,680,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. ContraFect employs 20 workers across the globe.View Additional Information About ContraFect.

What is ContraFect's official website?

The official website for ContraFect is http://www.contrafect.com/.

How can I contact ContraFect?

ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at 914-207-2300 or via email at [email protected]


MarketBeat Community Rating for ContraFect (NASDAQ CFRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  180 (Vote Outperform)
Underperform Votes:  163 (Vote Underperform)
Total Votes:  343
MarketBeat's community ratings are surveys of what our community members think about ContraFect and other stocks. Vote "Outperform" if you believe CFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Featured Article: Blockchain

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel